[{"id":"5d9e65c6-b900-41df-834e-6e18a16cdf9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470203","created_at":"2026-03-28T01:44:18.552Z","updated_at":"2026-03-28T01:44:18.552Z","phase":"","brief_title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","source_id_and_acronym":"NCT07470203","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/31/2026","start_date":" 03/31/2026","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"e2abfe31-044c-4950-add2-9dde133a5bcf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05426486","created_at":"2022-06-22T22:54:01.106Z","updated_at":"2025-02-25T12:28:52.301Z","phase":"Phase 2/3","brief_title":"A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients","source_id_and_acronym":"NCT05426486","lead_sponsor":"Caigang Liu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Irene (pyrotinib) • anvatabart opadotin (JNJ-0683)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 05/23/2022","start_date":" 05/23/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2024-10-30"},{"id":"7d4e0c5e-02b2-4147-b10a-d996c89682fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05659056","created_at":"2022-12-21T15:59:10.596Z","updated_at":"2024-07-02T16:35:09.330Z","phase":"Phase 2","brief_title":"Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer","source_id_and_acronym":"NCT05659056","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Irene (pyrotinib) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/29/2022","start_date":" 11/29/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-16"},{"id":"ac98ef23-c100-4250-a77b-e2d769f12f8d","acronym":"NCI-2020-02940","url":"https://clinicaltrials.gov/study/NCT04445844","created_at":"2021-01-18T21:23:42.652Z","updated_at":"2024-07-02T16:35:11.834Z","phase":"Phase 2","brief_title":"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study","source_id_and_acronym":"NCT04445844 - NCI-2020-02940","lead_sponsor":"Mridula George, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Zynyz (retifanlimab-dlwr) • Reolysin (pelareorep)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-04-02"},{"id":"a807a23b-d916-49a5-bf5d-9adada61ab5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861271","created_at":"2023-05-16T17:06:46.295Z","updated_at":"2024-07-02T16:35:13.295Z","phase":"Phase 2","brief_title":"Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer","source_id_and_acronym":"NCT05861271","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HR negative • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HR negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • capecitabine • Irene (pyrotinib) • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 1008","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-03-22"},{"id":"389ebfec-96d0-4ae7-9d59-0a96b42cf326","acronym":"","url":"https://clinicaltrials.gov/study/NCT06208410","created_at":"2024-01-17T18:20:05.757Z","updated_at":"2024-07-02T16:35:15.660Z","phase":"Phase 1/2","brief_title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","source_id_and_acronym":"NCT06208410","lead_sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Loqtorzi (toripalimab-tpzi) • capecitabine • Irene (pyrotinib) • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 01/11/2024","start_date":" 01/11/2024","primary_txt":" Primary completion: 02/26/2026","primary_completion_date":" 02/26/2026","study_txt":" Completion: 02/26/2026","study_completion_date":" 02/26/2026","last_update_posted":"2024-03-08"},{"id":"a9884f35-33d5-431c-829d-5643a5473a8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06035679","created_at":"2023-09-13T14:10:03.872Z","updated_at":"2024-07-02T16:35:17.229Z","phase":"","brief_title":"Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer","source_id_and_acronym":"NCT06035679","lead_sponsor":"Youzhi Zhu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Irene (pyrotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/17/2023","start_date":" 08/17/2023","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-02-28"},{"id":"4bfdbfd4-3bf6-4959-a48c-30dc58c15c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05575804","created_at":"2022-10-12T13:56:41.863Z","updated_at":"2024-07-02T16:35:17.616Z","phase":"Phase 1/2","brief_title":"GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT05575804","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Irene (pyrotinib) • GQ1001"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-26"},{"id":"728dc2c6-7c28-4dce-b181-48e56ea06694","acronym":"YOUNGBC-21","url":"https://clinicaltrials.gov/study/NCT05572645","created_at":"2022-10-10T15:07:07.451Z","updated_at":"2025-02-25T12:29:06.173Z","phase":"","brief_title":"Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab","source_id_and_acronym":"NCT05572645 - YOUNGBC-21","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)"],"overall_status":"Completed","enrollment":" Enrollment 333","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2024-02-26"},{"id":"907feaf5-e7e5-4d28-b0f2-b1324419c79c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05042791","created_at":"2021-09-13T14:55:58.528Z","updated_at":"2024-07-02T16:35:20.099Z","phase":"Phase 2","brief_title":"A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases","source_id_and_acronym":"NCT05042791","lead_sponsor":"Jiangxi Provincial Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Irene (pyrotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 362","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-02-09"},{"id":"ad8ff218-f482-4c2e-97da-fbf04e789fb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015048","created_at":"2023-08-29T16:10:03.670Z","updated_at":"2024-07-02T16:35:21.190Z","phase":"Phase 1/2","brief_title":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","source_id_and_acronym":"NCT06015048","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 364","initiation":"Initiation: 08/11/2023","start_date":" 08/11/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 12/29/2026","study_completion_date":" 12/29/2026","last_update_posted":"2024-02-02"},{"id":"d6a118c2-8cf3-4103-9203-82d15917f3c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06185400","created_at":"2023-12-29T18:18:16.940Z","updated_at":"2024-07-02T16:35:24.913Z","phase":"Phase 2","brief_title":"RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations","source_id_and_acronym":"NCT06185400","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Irene (pyrotinib) • Ameile (aumolertinib) • Aidixi (disitamab vedotin) • Ivesa (firmonertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-12-29"},{"id":"4acdced6-8493-4da3-a716-b92282a2153b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04144569","created_at":"2021-01-18T20:13:38.188Z","updated_at":"2024-07-02T16:35:25.154Z","phase":"Phase 2","brief_title":"PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC","source_id_and_acronym":"NCT04144569","lead_sponsor":"Yongchang Zhang","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-27"},{"id":"f56b977b-9d2c-4be8-bb3f-191550b47d48","acronym":"FUTURE-SUPER","url":"https://clinicaltrials.gov/study/NCT04395989","created_at":"2021-01-18T21:12:49.296Z","updated_at":"2024-07-02T16:35:25.372Z","phase":"Phase 2","brief_title":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.","source_id_and_acronym":"NCT04395989 - FUTURE-SUPER","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • famitinib (SHR 1020) • Airuituo (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 139","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-22"},{"id":"14d2eca8-7001-4e9e-8ac6-414eaae19b5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001086","created_at":"2023-08-21T15:09:06.500Z","updated_at":"2024-07-02T16:35:25.613Z","phase":"Phase 2","brief_title":"A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer","source_id_and_acronym":"NCT06001086","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-12-20"},{"id":"5099b846-9a06-490a-87e5-9edae2154cd9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05745740","created_at":"2023-02-27T15:01:09.062Z","updated_at":"2024-07-02T16:35:28.037Z","phase":"Phase 1/2","brief_title":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","source_id_and_acronym":"NCT05745740","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-27"},{"id":"668f9d85-e6e2-4063-88dd-6977ab94a708","acronym":"CORINNE-PI","url":"https://clinicaltrials.gov/study/NCT05910398","created_at":"2023-06-18T17:08:05.113Z","updated_at":"2024-07-02T16:35:28.457Z","phase":"Phase 3","brief_title":"Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer","source_id_and_acronym":"NCT05910398 - CORINNE-PI","lead_sponsor":"RenJi Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 488","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 04/01/2030","primary_completion_date":" 04/01/2030","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2023-11-21"},{"id":"66ea9b1f-2f0f-4a69-9665-01061a13c039","acronym":"NeoATP","url":"https://clinicaltrials.gov/study/NCT04126525","created_at":"2021-01-18T20:09:32.713Z","updated_at":"2024-07-02T16:35:28.431Z","phase":"Phase 2","brief_title":"Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer","source_id_and_acronym":"NCT04126525 - NeoATP","lead_sponsor":"RenJi Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • paclitaxel • Irene (pyrotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 10/28/2021","primary_completion_date":" 10/28/2021","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-11-21"},{"id":"b8620f9d-6931-4687-bdce-783dc308b8a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04254263","created_at":"2021-01-18T20:40:19.951Z","updated_at":"2024-07-02T16:35:28.487Z","phase":"Phase 3","brief_title":"Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer","source_id_and_acronym":"NCT04254263","lead_sponsor":"RenJi Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Irene (pyrotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 12/16/2019","start_date":" 12/16/2019","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2023-11-21"},{"id":"028c43a2-0cf3-48a1-b26a-5ef9cd321143","acronym":"PILHLE-001","url":"https://clinicaltrials.gov/study/NCT05165225","created_at":"2021-12-21T15:53:34.083Z","updated_at":"2024-07-02T16:35:29.122Z","phase":"Phase 2","brief_title":"Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial","source_id_and_acronym":"NCT05165225 - PILHLE-001","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Irene (pyrotinib) • cyclophosphamide • epirubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2023-11-15"},{"id":"b195aa71-00ee-4ed5-a0ad-edf29d971b87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769010","created_at":"2023-03-15T14:02:15.990Z","updated_at":"2024-07-02T16:35:32.713Z","phase":"Phase 2","brief_title":"Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases","source_id_and_acronym":"NCT05769010","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-10-19"},{"id":"ab67aa4e-3706-4bb1-9ddb-654da25dc17d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05328440","created_at":"2022-04-14T11:53:41.939Z","updated_at":"2024-07-02T16:35:35.894Z","phase":"Phase 2","brief_title":"Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)","source_id_and_acronym":"NCT05328440","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER negative • EGFR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Irene (pyrotinib) • fulvestrant • AiRuiKang (dalpiciclib) • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-09-25"}]